Retina News

9/1/2010

LEDs Illuminate Eye For Ocular Disease Screening

A new imaging system using six different wavelengths to illuminate the interior of the eyeball (ocular fundus) may pave the way for doctors to easily screen patients for common diseases of the eye, such as age-related macular degeneration and diabetic retinopathy. The system is described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics.

Source: American Institute of Physics


8/31/2010

Alimera Sciences' Iluvien(R) Receives FDA Priority Review for the Treatment of Diabetic Macular Edema

ATLANTA, Aug 30, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien(R) (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

Source: Alimera Sciences, Inc


8/31/2010

Pneumatic Retinopexy May Help Avoid OR-Based Surgery

Pneumatic retinopexy remains a plausible intervention for rhegmatogenous retinal detachment and may prevent the need for operating room-based surgical intervention.

Source: Ocular Surgery News


8/31/2010

PSivida Announces IluvienĀ® Receives FDA Priority Review For Treatment Of Diabetic Macular Edema

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences (NASDAQ:ALIM) has been notified that the U.S. Food and Drug Administration (FDA) has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien for the treatment diabetic macular edema (DME).

Source: BUSINESS WIRE


8/30/2010

Retinal Vein Occlusion Associated With Higher Rate Of Stroke

Patients with retinal vein occlusions appear to have significantly more comorbidities, as well as an increased risk for cerebrovascular accident.

Source: Ocular Surgery News


8/26/2010

Kowa Optimed Announces Ronald Kaiser As Vice President Of Medical Sales

Kowa Optimed, Inc., a leading innovator of integrated ophthalmic diagnostic systems, has named Ronald Kaiser as its newly appointed Vice President of Medical Sales effective September 1st, 2010. A well-accomplished writer and lecturer, bringing over 36 years of experience in the Medical/ Ophthalmic field, Kaiser is ideally suited to lead Kowa Optimed's medical sales team, as well as directly contribute to the company's overall growth. Kaiser most recently served as the National Sales and Marketing Manager at Canon U.S.A. Inc., where he was responsible for Sales activities in the USA, Latin America and Canada as well as new product development projects and new business opportunities.

Source: Kowa Optimed, Inc.


8/25/2010

Smaller-Gauge Instruments Easier To Manipulate For Posterior Capsulotomy, Anterior Vitrectomy In Pediatric Eyes

Use of smaller-gauge instruments to perform posterior capsulotomy and anterior vitrectomy may give the surgeon advantages during cataract surgery on pediatric patients while also limiting the occurrence of posterior capsule opacification.

Source: Ocular Surgery News


8/24/2010

New BioTrends Report Highlights The Current Treatment Approaches And Major Drivers Of Prescribing Choice For Noninfectious Uveitis

BioTrends Research Group, Inc. is pleased to announce the publication of a new syndicated report, TreatmentTrendsĀ®: Noninfectious Uveitis. This report, based on feedback gathered in an on-line survey completed by 72 retinal specialists in June/July 2010, addresses the medical management of noninfectious uveitis (anterior, intermediate, posterior and panuveitis) and referral/co-management patterns between retinal specialists and other specialties.

Source: BioTrends Research Group, Inc.


8/20/2010

Breakthrough Gene Therapy Prevents Retinal Degeneration

In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls. The study, published online in advance of print in Molecular Therapy, brings researchers closer to a non-viral gene therapy treatment for degenerative eye disorders.

Source: Tufts University


8/19/2010

Poverty - Not Sight Loss - Explains Low Quality Of Life For Visually Impaired People, Says New Research

In a startling reversal of popular assumptions new research commissioned by Thomas Pocklington Trust shows that when people with sight loss suffer depression and low quality of life it is more to do with low incomes, ill health and lack of social participation, than it is to do with their loss of vision.

Source: Medical News Today

Next Page

Sponsored by

The most likely diagnosis is:




 
advertisement
Advertisement (image not found)

Upcoming Events

Newsletters













Write For Us

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing